Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): Interleukin 10 and interferon γ may be critical mediators for the development of autologous GVHD

Blood

Volumn 100, Issue 7, 2002, Pages 2650-2658

  Miura, Yuji ^a,b   Thoburn, Christopher J ^a,b   Bright, Emilie C ^a,b   Chen, Weiran ^a,b   Nakao, Shinji ^a,b   Hess, Allan D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; PHYTOHEMAGGLUTININ; RANTES; RECOMBINANT GAMMA INTERFERON; THIOTEPA;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD; BREAST CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; ERYTHEMA; FEMALE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN POLYMORPHISM; SKIN BIOPSY; T LYMPHOCYTE;

EID: 0036788725     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0176     Document Type: Article

References (74)

1. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-838.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
3. Nademanee A, Schmidt GM, O'Donnell MR, et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood. 1992;80:1130-1134.
4. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol. 1994;12:2543-2551.
5. Verdonck LF, van Putten WLJ, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1994;332:1045-1051.
6. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515-521.
7. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoletic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069-1076.
8. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
9. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reaction after bone marrow transplantation. Blood. 1990;75:555-562.
10. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-653.
11. Glazier A, Tutschika PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporine treated rats after syngeneic autologous bone marrow reconstitution. J Exp Med. 1983;158:1-8.
12. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation, I: development of cytotoxic T lymphocytes with apparent polyclonal anti-la specificity, including autoreactivity. J Exp Med. 1985;161:718-730.
13. Jones RJ, Vogelsang GB, Hess AD, et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet. 1989;333:754-756.
14. Fischer AC, Beschorner WE, Hess AD. Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med. 1989;169:1031-1041.
15. + T lymphocyte subsets. J Immunol. 1990;145:526-533.
16. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood. 1994;84:2061-2067.
17. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood. 1992;79:3031-3035.
18. Vogelsang G, Bitton R, Piantadosi S, et al. Immune modulation in autologous bone marrow transplantation: cyclospodne and gamma-interferon trial. Bone Marrow Transplant. 1999;24:637-640.
19. Marin GH, Porto A, Prates V, et al. Graft versus host disease in autologous stem cell transplantation. J Exp Clin Cancer Res. 1999;18:201-208.
20. Miura Y, Ueda M, Zeng W, et al. Induction of autologous graft-versus-host disease with cyclosporine A after peripheral blood stem cell transplantation: analysis of factors affecting induction. J Allergy Clin Immunol. 2000;106:51-57.
21. Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD. Successful in vitro graft-versus-tumor effect against an la-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood. 1989;74:1165-1171.
22. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood. 1997;89:2203-2209.
23. Hess AD, Thoburn CJ. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol Rev. 1997;157:111-123.
24. Hess AD, Thoburn C, Horwitz L. Promiscuous recognition of major histocompatibility complex class II determinants in cyclosporine-induced syngeneic graft-versus-host disease: specificity of cytolytic effector T cells. Transplant. 1998;65:785-792.
25. Miura Y, Thoburn CJ, Bright EC, et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood. 2001;98:868-876.
26. Dolei A, Capobianchi MR, Ameglio F. Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta. Infect Immun. 1983;40:172-176.
27. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD. Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother. 1992;1:75-84.
28. Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Curr Opin Immunol. 1999;11:509-515.
29. Deeg HJ. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction. Int J Hematol. 2001;74:26-32.
30. + T cells. J Immunol. 1998;160:3188-3193.
31. Suda T, O'GarraA, MacNeil I, Fischer M, Bond MW, Zlotnik A. Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. Cell Immunol. 1990;129:228-240.
32. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood. 1995;85:842-851.
33. Fujll SI, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood. 2001;98:2143-2151.
34. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
35. Bejarano MT, de Waal Malefyt R, Abrams JS, et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol. 1992;4:1389-1397.
36. + T cell clones and resting T cells: specific inhibition of IL-2 production and proliferation. J Immunol. 1993;150:4754-4765.
37. + T cells. J Exp Med. 1996;184:19-29.
38. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-742.
39. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915-924.
40. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 1993;151:1224-1234.
41. van der Wall E, Horn T, Bright E, et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer. 2000;83:1405-1411.
42. Bernard D, Maurizis JC, Ruse F, et al. Presence of HLA-D/DR antigens on the membrane of breast tumour cells. Clin Exp Immunol. 1984;56:215-221.
43. Natali PG, Giacomini P, Bigotti A, et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res. 1983;43:660-668.
44. Fischer AC, Ruvolo PP, Burt R, et al. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease: a highly conserved repertoire mediates autoaggression. J Immunol. 1995;154:3713-3725.
45. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
46. Held CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
47. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97:3146-3151.
48. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet. 1997;349:1912-1913.
49. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
50. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941-3946.
51. Eskdale J, McNicholl J, Wordsworth P, et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet. 1998;352:1282-1283.
52. Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood. 1999;93:43-50.
53. + T cells to the liver, lung, and spleen during graft-versus-host disease. Blood. 2000;96:2973-2980.
54. + T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo. J Immunol. 1999;162:5423-5428.
55. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Hulzinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A. 1998;95:9465-9470.
56. Lopatin U, Yao X, Williams RK, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood. 2001;97:3161-3170.
57. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995;4:393-395.
58. Cush JJ, Splawski JB, Thomas R, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:96-104.
59. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A. 2000;97:14467-14472.
60. Kube D, Platzer C, von Knethen A, et al. Isolation of the human interleukin 10 promoter: characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 1995;7:1-7.
61. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101-1108.
62. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994;179:493-502.
63. + lymphoid engraftment. J Immunol. 1994;152:1004-1013.
64. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature. 1988;336:176-179.
65. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell. 1987;49:273-280.
66. Aguilar LK, Aguilar-Cordova E, Cartwright J Jr, Belmont JW. Thymic nurse cells are sites of thymocyte apoptosis. J Immunol. 1994;152:2645-2651.
67. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988;241:1655-1658.
68. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol. 1990;145:4167-4173.
69. Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol. 1991;147:528-534.
70. Rohrer JW, Coggin JH Jr. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol. 1995;155:5719-5727.
71. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183:2645-2656.
72. Braun MY, Lowin B, French L,Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 1996;183:657-661.
73. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA41g on murine graft-versus-host disease (GVHD) development: CTLA41g prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol. 1996;157:4258-4267.
74. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.